Hôpital l'Archet 1
- Address
- CHU NIce, 151 route de Saint-Antoine de Ginestière, 06200 Nice, France
Hôpital l'Archet 1
Hôpital l'Archet 1 is a specialized medical research center engaged in advanced clinical trials addressing both pediatric and adult hematologic and oncologic conditions. The center demonstrates particular expertise in developing innovative treatment protocols for patients with challenging malignancies requiring complex therapeutic approaches.
- Diffuse intrinsic pontine glioma (DIPG) and diffuse midline gliomas in children, adolescents, and adults
- High-risk myeloid malignancies treated with allogeneic stem cell transplantation
- Novel biological medicines and conditioning regimens combining targeted therapies with radiotherapy
The research program includes cutting-edge studies evaluating ONC201 and everolimus for H3K28M-mutant and EZHIP-positive brain tumors, as well as optimization of busulfan-based conditioning regimens for hematopoietic stem cell transplantation. The center's commitment spans from pediatric neuro-oncology to complex allogeneic transplantation protocols, focusing on improving progression-free survival in patients with poor prognosis malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Institut Gustave Roussy1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital l'Archet 1
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of ONC201 and Everolimus with Radiotherapy in Newly Diagnosed Diffuse Midline Gliomas H3K28M Mutant or EZHIP Positive Patients | Institut Gustave Roussy | Phase III | Recruiting | Oct 2014 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One | 1 | Unknown | 2014-10-01 | 2014-10-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.